Harnessing aptamers against COVID-19: A therapeutic strategy

The novel coronavirus crisis caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was a global pandemic. Although various therapeutic approaches were developed over the past 2 years, novel strategies with more efficient applicability are required to target new variants. Aptamers ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmoudi, Ali, Alavizadeh, Seyedeh Hoda, Hosseini, Seyedeh Atefeh, Meidany, Pouria, Doagooyan, Maham, Abolhasani, Yasaman, Saadat, Zakieh, Amani, Fatemeh, Kesharwani, Prashant, Gheybi, Fatemeh, Sahebkar, Amirhossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Post-Screen
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266562/
https://www.ncbi.nlm.nih.gov/pubmed/37315763
http://dx.doi.org/10.1016/j.drudis.2023.103663
Descripción
Sumario:The novel coronavirus crisis caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was a global pandemic. Although various therapeutic approaches were developed over the past 2 years, novel strategies with more efficient applicability are required to target new variants. Aptamers are single-stranded (ss)RNA or DNA oligonucleotides capable of folding into unique 3D structures with robust binding affinity to a wide variety of targets following structural recognition. Aptamer-based theranostics have proven excellent capability for diagnosing and treating various viral infections. Herein, we review the current status and future perspective of the potential of aptamers as COVID-19 therapies.

Ejemplares similares